期刊文献+

呋塞米对心衰大鼠心功能及心肌纤维化的影响 被引量:7

Effect of furosemide on cardiac function and myocardial fibrosis in heart failure rats
下载PDF
导出
摘要 目的探讨呋塞米对心肌梗死后心力衰竭大鼠心功能及心肌纤维化的影响。方法采用结扎冠状动脉左前降支构建心肌梗死后心力衰竭大鼠模型。术后2周将34只大鼠随机分为3组:假手术组(10只,生理盐水)、心衰对照组(12只,生理盐水)及呋塞米组[12只,20 mg/(kg·d)]。药物干预4周后分别行超声心动图、血流动力学、心肌Masson染色,测定胶原容积分数(CVF)、血浆血管紧张素Ⅱ(AngⅡ)、醛固酮以及心肌转化生长因子β1(TGF-β1)和胶原纤维Ⅲ(CollagenⅢ)mRNA的表达。结果与心衰对照组比较,呋塞米组的左室舒张末期压(LVEDP)明显升高(P<0.05),而射血分数(EF)升高不明显。呋塞米组的AngⅡ、醛固酮、CVF及TGF-β_1和Collagen Ⅲ mRNA的表达均显著升高(P<0.05)。结论呋塞米能进一步激活心衰大鼠的肾素-血管紧张素-醛固酮系统(RAAS),进而升高TGF-β水平,促进心肌纤维化重构,最终加剧心功能的恶化。 Objective To explore the effect of furosemide on cardiac function and myocardial fibrosis in rats with heart failure after myocardial infarction.Methods Heart failure was produced by ligation of the left anterior descending coronary artery in rats.Two weeks after the ligation 34 rats were randomly divided into 3 groups:Sham operation group(n = 10),heart failure group(n = 12) and furosemide group(n = 12).Echocardiography,hemodynamic measurements,Masson's trichrome staining and collagen volume fraction,plasma angiotensin Ⅱ and aldosterone levels the mRNA expression of TGF-β and Collagen Ⅲ in the myocardium were detected at four weeks after drug intervention.Results Compared with the heart failure group the left ventricular end diastolic pressure(LVEDP) in furosemide group was significantly higher(P〈0.05) but no significant difference was found in ejection fraction(EF).In addition plasma angiotensin Ⅱ and aldosterone levels,myocardial collagen volume fraction and the mRNA expression of TGF-β and Collagen Ⅲ increased significantly(P〈0.05).Conclusion Furosemide can further activate the heart failure RAAS,and increase TGF-β level,promote the reconstruction of myocardial fibrosis,ultimately exacerbate the deterioration of cardiac function.
作者 罗经宏 李玲
出处 《实用药物与临床》 CAS 2016年第1期18-21,共4页 Practical Pharmacy and Clinical Remedies
关键词 心力衰竭 呋塞米 心功能 纤维化重构 Heart failure Furosemide Cardiac function Myocardial fibrosis
  • 相关文献

参考文献11

  • 1Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update:a report from the American Heart Association I J 1. Circulation, 2010,123 : el 8 -e209.
  • 2Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive sum- mary:heart disease and stroke statistics-2010 update: a report from the American Heart Association [ J]. Circulation, 2010, 121:948-954.
  • 3安芳,王林.利尿剂的不良反应及对心力衰竭预后影响的研究进展[J].心血管病学进展,2011,32(2):205-208. 被引量:6
  • 4李建辉,郝国贞.襻利尿剂在心力衰竭治疗中的应用进展[J].河北医药,2011,33(22):3466-3467. 被引量:2
  • 5Fads R, Flather M, Purcell H, et al. Current evidence sup- porting the role of diuretics in heart failure: a meta analysis of randomised controlled trials [ J ]. Int J Cardiol, 2002,82 ( 2 ) : 149-158.
  • 6Fads R,Purcell H,Poole-Wilson PA,et al. Diuretics for heart fail- ure [ J ]. Cochrane Database Syst Rev ,2006, ( 1 ) :3838-3841.
  • 7Eshagllian S, Horwich TB, Fonamw GC. Relation of loop diu- retics dose to mortality in advanced heart failure E J ]. Am J Cardio1,2006,97 ( 12 ) : 1759-1764.
  • 8Sata Y, Krum H. The future of pharmacological therapy for heart failure [ J ]. Circ J,2010,74 (5) : 809-817.
  • 9Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis [ J ]. J Cell Physiol, 2010, 225(3) :631-637.
  • 10Dobaczewski M, Bujak M, Li N, et al. Smad3 signaling criti- cally regulates fibroblast phenotype and function in healing myocardial infarction I J ]. Circ Res,2010,107:418-428.

二级参考文献38

  • 1陈灏珠.心脏病学.第7版.北京:人民卫生出版社,2007:402.
  • 2Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005[J]. Eur Heart J, 2005, 26(7) :644-649.
  • 3Jhund PS, McMurray JV, Davie AP. The acute vascular effects of fmsemide in heart failure[J]. Br J Clin Pharmacol, 2000, 50(1 ) :9-13.
  • 4Kiely DG, Cargill RI, Lipworth BJ. Effects of frusemide and hypoxia on the pulmonary vascular bed in man[J]. Br J Clin Pharmacol, 1997, 43(3) :309- 313.
  • 5McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of lefl ventricular dysfunction in experimental heart failure[ J]. J Am Coil Cardiol, 2004, 44(6) : 1301-1307.
  • 6Yasutomo H, Akiko K, Mizuho T, et al. Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemlde in healthy dogs [ J]. Am J Vet Res, 2008, 69 (12) : 1664-1669.
  • 7Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy[J]. Circulation, 2002, 105( 11 ) :1348-1353.
  • 8Sampath S, Moran JL, Graham PL, et al. The efficacy of loop diuretics in acute renal failure: assessment using Bayesian evidence synthesis techniques [ J ]. Crit Care Med, 2007, 35( 11 ):2516-2524.
  • 9Adams KF, Fonamw GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompecate Heart Failure National Registry (ADHERE) [J]. Am Heart J, 2005, 149(2) : 209-216.
  • 10Anand I, Florea VG. Diuretics in chronic heart failure - benefits and hazards [J]. Eur Heart J, 2001, 3(suppl G) :G8-G18.

共引文献6

同被引文献54

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部